Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study
Randomized trial showed subcutaneous isatuximab improved patient satisfaction in East Asian RRMM patients, suggesting benefits over intravenous administration.
Key Points
This research aimed to evaluate the non-inferiority of subcutaneous isatuximab compared to intravenous isatuximab in relapsed/refractory multiple myeloma patients in East Asia.
Multicenter, open-label trial enrolling patients with relapsed/refractory multiple myeloma aged ≥18 years.
Patients were randomized 1:1 to receive isatuximab subcutaneous or intravenous alongside pomalidomide and dexamethasone.
Endpoints included overall response rate, observed isatuximab concentration, and patient satisfaction measured by a questionnaire.
Overall response rates were 74.0% for subcutaneous and 70.9% for intravenous administration.
Subcutaneous administration resulted in higher patient satisfaction rates at 64.0% versus 52.7% for intravenous.
Infusion reactions occurred in 0% of the subcutaneous group compared to 21.8% in the intravenous group.